Lercanidipina Aurovitas

Lercanidipine, the active ingredient in Lercanidipina Aurovitas, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by promoting vascular relaxation and lowering blood pressure.

GNH USA supplies Lercanidipina Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is used to manage high blood pressure, acting on the vascular smooth‑muscle calcium channels that regulate tone.

- Essential hypertension: reduces systolic and diastolic pressure in patients with primary high blood pressure. - Isolated systolic hypertension: lowers elevated systolic readings, especially in older adults. - General hypertension: helps achieve target blood pressure levels as part of antihypertensive therapy.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: warm sensation with reddening of skin. - Peripheral edema: swelling of ankles or feet. - Dizziness: especially upon standing. - Tiredness: general feeling of fatigue. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angio‑edema: rapid swelling of face, lips, or throat. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, itching, or anaphylaxis. - Cardiac arrhythmias: irregular heart rhythms. - Renal impairment: worsening kidney function.

Before initiating therapy, consider patient‑specific factors and monitor for potential risks. - Pregnancy: safety not established; avoid unless clearly needed. - Breastfeeding: unknown excretion; weigh benefits against risks. - Liver disease: use with caution; dose adjustment may be required. - Elderly: monitor for orthostatic hypotension and renal function. - Drug interactions: review concomitant medications for additive blood‑pressure effects. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Lercanidipine can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels and risk of hypotension. - Grapefruit juice: can elevate drug concentration leading to adverse effects.

Moderate Interactions (Monitor Closely):\n- Other antihypertensives (e.g., ACE inhibitors, diuretics): may cause additive blood‑pressure lowering. - Simvastatin or other CYP3A4 substrates: may increase statin exposure, raising myopathy risk. - Beta‑blockers: monitor for excessive bradycardia or hypotension. - NSAIDs: may attenuate antihypertensive effect. - Alcohol: can enhance vasodilatory effects, leading to dizziness.